Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CHXOY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CD2 RPA2.10 D265C/H435A ADC C
|
|||||
| Synonyms |
CD2-RPA2.10-D265C/H435A-ADC-C
Click to Show/Hide
|
|||||
| Organization |
Heidelberg Pharma Research GmbH
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2.1
|
|||||
| Structure |
|
|||||
| Antibody Name |
CD2 RPA2.10 D265C/H435A
|
Antibody Info | ||||
| Antigen Name |
T-cell surface antigen CD2 (CD2)
|
Antigen Info | ||||
| Payload Name |
Alpha-amanitin (thioether)
|
Payload Info | ||||
| Therapeutic Target |
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
|
Target Info | ||||
| Linker Name |
Maleimido-caproyl
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the engineered cysteine (THIOMAB).
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.